Pharmaco-kinetics of current skeletal-seeking radiopharmaceuticals

The blood clearance of all current bone-seeking radiopharmaceuticals is biexponential during the first four hours after injection. Exponent I represents bone uptake and its clearance half-time is less than 30 min. Exponent II represents mainly urinary excretion and its clearance half-time varies from 168 to 512 min. The blood background is highest with 99mTc-labeled polyphosphate (Tc-Poly) and lowest with sodium fluoride (F-18); 99mTc-labeled diphosphonate (Tc-Dip) and 99mTc-labeled pyrophosphate (Tc-Pyro) show intermediate blood levels. The slower blood clearance of 99mTc-phosphate complexes in comparison with F-18 is due primarily to their increased protein binding. Tc-Poly blood clearance, which is slower than that of Tc-Dip and Tc-Pyro, is due primarily to its increased red cell binding and the larger size of its molecule. Bone uptake and urinary excretion of all 99mTc-labeled phosphate complexes are approximately the same: in the range of six to ten per cent in the blood, 30-33% in the urine, and 55-58 percent in the bone and other tissues. F-18 concentration in the bone is almost 1.5 times that of the 99mTc-labeled phosphate complexes. The sensitivity and resolution of lesions are identical for all 99mTc-labeled phosphate complexes and are far better than those for F-18. No toxicity is noted with the amount of phosphate present in the marketed kits, and it appears reasonable to use the minimal amount so long as efficiency is not compromised.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?